ライフサイエンスコーパス: hyperfractionate

1 py with either total-body irradiation (TBI) (hyperfractionated 15 Gy)/melphalan (180 mg/m(2)) or thio

2 ence between the study treatment (continuous hyperfractionated accelerated radiotherapy [CHART]) and

3 CHART (continuous hyperfractionated accelerated radiotherapy) is the most

4 rvations, we developed the CHART (continuous hyperfractionated accelerated radiotherapy) regimen, whi

5 of radiation (RT) in both standard daily and hyperfractionated-accelerated (HA) twice-daily RT schedu

6 nce-daily RT cohorts) or 1.5 Gy twice a day (hyperfractionated cohorts).

7 eived induction chemotherapy, dose-escalated hyperfractionated craniospinal radiotherapy, and mainten

8 to conventionally fractionated CRT (CFX) or hyperfractionated CRT (HFX) to a total dose of 18 Gy.

9 BP patients received hyper-CVAD (hyperfractionated cyclophosphamide, vincristine, adriamy

10 ients with Ph(+) ALL who received first-line hyperfractionated cyclophosphamide, vincristine, doxorub

11 Patients received eight cycles of hyperfractionated cyclophosphamide, vincristine, doxorub

12 st reported results have been with rituximab-hyperfractionated cyclophosphamide-vincristine-doxorubic

13 ard) or twice daily for 2 consecutive weeks (hyperfractionated) during a 21-day cycle.

14 platin chemotherapy (100 microg/delivery) or hyperfractionated external beam radiotherapy (EBRT; 15 G

15 of two chemotherapy arms administered before hyperfractionated external-beam radiotherapy (HFEBRT).

16 all survival benefit being restricted to the hyperfractionated group (HR 0.83, 0.74-0.92), with absol

17 is more efficacious and not more toxic than hyperfractionated irradiation alone.

18 otherapy (combined treatment) is superior to hyperfractionated irradiation alone.

19 We investigated whether hyperfractionated irradiation plus concurrent chemothera

20 d and neck cancer who were treated only with hyperfractionated irradiation received 125 cGy twice dai

21 ped in three types of altered fractionation: hyperfractionated, moderately accelerated, and very acce

22 In lung cancer, randomized trials assessing hyperfractionated or accelerated radiotherapy seem to yi

23 mg/m2 per day, 7 days per week, plus pelvic hyperfractionated radiation 55.2 to 60 Gy at 1.2 Gy bid

24 sophagitis >/= grade 3 in patients receiving hyperfractionated radiation and chemotherapy.

25 e and tolerable concomitant chemotherapy and hyperfractionated radiation regimen that induces sustain

26 cell head and neck cancer were treated with hyperfractionated radiation therapy (72 Gy at 1.2 Gy twi

27 fluorouracil administration and accelerated, hyperfractionated radiation therapy.

28 ean age = 51.6 yrs) received conventional or hyperfractionated radiotherapy (63-76.8 Gy) for primary

29 aged and randomly assigned to treatment with hyperfractionated radiotherapy (HFRT) or standard (conve

30 mucositis, dysphagia, and xerostomia during hyperfractionated radiotherapy (n = 40) but not standard

31 The comparison between hyperfractionated radiotherapy and concomitant chemoradi

32 Split-course hyperfractionated radiotherapy did not increase the rate

33 low-up than the first version of MARCH, that hyperfractionated radiotherapy is, along with concomitan

34 ms to confirm and explain the superiority of hyperfractionated radiotherapy over other altered fracti

35 ompared with conventional radiotherapy, with hyperfractionated radiotherapy showing the greatest bene

36 In hyperfractionated radiotherapy the dose per fraction is

37 livered in daily 2-Gy fractions to 70 Gy, or hyperfractionated radiotherapy was delivered in 1.25-Gy

38 mide, and vincristine, and a split course of hyperfractionated radiotherapy.

39 a significant OS benefit from accelerated or hyperfractionated radiotherapy; a similar but nonsignifi

40 Forty patients (30 standard and 10 hyperfractionated) received 533 injections of ONYX-015.

41 ain (47% on the standard regimen, 80% on the hyperfractionated regimen).

42 Gy/d), and the final three patients received hyperfractionated RT (76.8 Gy, 1.2 Gy bid).

43 zed to receive conventional RT (C-RT) versus hyperfractionated RT (HF-RT).

44 A greater difference was evident for hyperfractionated RT and platinum-based chemotherapy.

45 Concurrent chemoradiotherapy with hyperfractionated RT is feasible in this patient populat

46 Subset analysis of studies using hyperfractionated RT revealed OS RR for ERT versus LRT o

47 we added paclitaxel to the FHX base and used hyperfractionated RT to determine the maximum-tolerated

48 The addition of infusional paclitaxel and hyperfractionated RT to FHX is feasible.

49 s whether shortening treatment duration with hyperfractionated RT would be feasible and improve locor

50 matched allogeneic sibling transplants using hyperfractionated TBI and cyclophosphamide for patients

51 Radiation consisted of accelerated hyperfractionated thoracic radiation (AHTRT) 1.5 Gy bid

52 e (PIEo) given concurrently with accelerated hyperfractionated thoracic radiation was studied in pati

53 The cytoreductive regimen consisted of hyperfractionated total body irradiation (HFTBI), thiote

54 ied allogeneic HLA-matched sibling BMT after hyperfractionated total body irradiation (TBI) and cyclo

55 tive and graft-versus-host disease regimens (hyperfractionated total body irradiation, cyclophosphami

56 ed myeloablative cytoreduction consisting of hyperfractionated total body irradiation, thiotepa, and

57 Hyperfractionated treatment resulted in 10% complete res

58 a randomized clinical trial to test whether hyperfractionated (twice daily) cranial radiation therap

59 mozolomide (TMZ), and rituximab, followed by hyperfractionated whole-brain radiotherapy (hWBRT) and s